GSK Eyes Development Of Ebola Vaccine | Chemical & Engineering News
Volume 92 Issue 33 | p. 17 | Concentrates
Issue Date: August 18, 2014

GSK Eyes Development Of Ebola Vaccine

Department: Business
Keywords: Ebola, vaccines, drug discovery

GlaxoSmithKline says it is in discussions with regulators about beginning Phase I clinical trials of an Ebola vaccine candidate. GSK acquired the product as part of its May 2013 purchase of the Swiss vaccines firm Okairos for $325 million. The British drugmaker says it is working with NIH’s Vaccine Research Center to advance development of what is now an early-stage candidate. It cautions that clinical development for a new vaccine can take 10 or more years and that accelerating the process is difficult.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment